Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis Using Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis

Key Points

• Outcomes indicate improved survival rates among patients receiving cyclophosphamide-based GVHD prophylaxis.
• Notable metrics include a 70% reduction in acute GVHD instances in treated patients.
• Analysis of transplant outcomes was conducted over a three-year period involving multiple centers.
• Findings support the use of cyclophosphamide to enhance the efficacy of GVHD prevention strategies.